You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
朗生醫藥(00503.HK)2019年度純利升11368.1%至1834.9萬美元
格隆匯 03-31 21:45

格隆匯3月31日丨朗生醫藥(00503.HK)公佈,截至2019年12月31日止年度,實現收入5425.7萬美元,同比下降4.6%;毛利3332.9萬美元,同比增長10.1%;公司擁有人應占純利1834.9萬美元,同比增長11368.1%;每股基本盈利4.54美仙,董事不建議派發末期股息。

盈利大幅增長主要歸於:(1)於年內,集團自有專科藥產品(包括帕夫林、新適確得等)收入較去年上升770萬美元,抵銷代理產品收入下降,但由於自有專科藥產品的毛利率較代理產品為高,所以集團的整體毛利上升;

(2)2019年年度因部分出售司太立的股份所錄得的收益較2018年年度大幅增加;及

(3)淨利潤被以下原因部分抵銷:(i)無形資產撥備;及(ii)公司於2019年6月21日就不行使認沽萃健控股有限公司期權發出公告,集團因認沽萃健期權撇銷而錄得損失。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account